ClinicalTrials.gg
RecruitingNCT07223333Updated Sep 29, 2026

A Study of PATAS Using Single Ascending Doses in Healthy Volunteers and Multiple Ascending Doses in Diabetic Subjects

A Phase 1 interventional study of PATAS Trifluoroacetate and Placebo in Type 2 Diabetes, sponsored by AdipoPharma LLC. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by AdipoPharma LLC · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.
Updated Sep 29, 2026Now RecruitingSite recruiting status changed+9 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States — 345 open to participants now, 479 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Planned enrollment
1,806th of 2,961
56 · median 90
Started
2026
with 157 others
Phase 1
384 of 3,308
25 open now
Primary completion
2027-05
later than 249 of 477 live
Registered
3,149th of 3,308
by date

Among the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 1,806th largest by planned enrollment of the 2,961 interventional ones that give a count, is one of 158 that started in 2026, is one of 384 in phase 1, reaches primary completion later than 249 of the 477 other live ones, and was the 3,149th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

345 of the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

340 more — sign in →

All 345 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

This is 2-part study. The primary objective of Part 1 is to evaluate safety and tolerability of single subcutaneous (SC) doses of PATAS in healthy subjects. The secondary objective of this study is to determine the pharmacokinetics (PK) of single SC doses of PATAS in healthy subjects. The primary objectives of Part 2 are to evaluate the safety and tolerability of 4 weekly SC doses of PATAS in subjects with T2D; and to determine the PK and pharmacodynamics (PD) of 4 weekly SC doses of PATAS in subjects with T2D. Secondary objectives of Part 2 include evaluation of the potential effect of multiple SC doses of PATAS on markers of glycemic control, as measured by glucose levels, insulin levels, and other metabolomic biomarkers and characterization of of adverse event (AE) profiles of the various dose levels of PATAS.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • Type 2 diabetes
  • insulin resistance
04

Who can participate

The criteria were revised on the registry on Sep 25, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Part 1: Single Ascending Dose Inclusion criteria

    1. Healthy male and female subjects, 18 to 55 years of age, inclusive, at the time of signing the Form (ICF);
    2. Willing and able to give written informed consent for participation in the study prior to the initiation of any Screening or study-specific procedures;
    3. (BMI) within the range of 20.0 to 35.0 kg/m2, inclusive, at Screening;
    4. In generally good health, as judged by the Investigator, based upon medical/surgical history and the results of physical examination, vital signs, clinical laboratory assessments, and 12-lead (ECG) at Screening and at Check-In (Day -1);
    5. Female subjects must have a negative serum pregnancy test result at the Screening Visit and a negative urine pregnancy test at Check-In (Day -1) (prior to the first dose of study drug) and must not be pregnant, lactating, or planning a pregnancy from the Screening Visit to 90 days after the last dose of study drug;
    6. Negative test result for severe acute respiratory syndrome coronavirus 2 at Check-In (Day -1); and
    7. Willing to comply with all study procedures and requirements throughout the duration of the study.

Exclusion criteria

Exclusion Criteria:

<!-- -->

  1. history of asthma, eczema, or any other allergic condition or previous severe ; Note: Non-active hay fever is not exclusionary.
  2. Liver function tests ( [ALT], aspartate aminotransferase [AST], alkaline phosphatase [ALP], total ) outside the following (ULNs) at Screening or at Check-In (Day -1): a. For ALT and AST, measurements > ULN; b. For ALP, measurements >ULN; or c. For total bilirubin, measurements > ULN.
  3. Estimated \</= 90 mL/min/1.73 m2 based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation at Screening or at Check-In (Day -1);
  4. Thyroid-stimulating hormone (TSH) outside of reference range (e.g., TSH \<1 × lower limit of normal [LLN] or TSH >1 × ULN) at Screening; Note: Abnormal TSH results will reflex to a free thyroxine (T4) test.
  5. History of unexplained syncope, cardiac arrest, unexplained cardiac arrythmias or torsades de pointes, or structural heart disease;
  6. Personal or family history of long syndrome;
  7. Clinically significant history of any disease or disorder (i.e., gastrointestinal, cardiovascular, respiratory, renal, hepatic, neurological, dermatological, psychiatric, or metabolic) deemed to be exclusionary, as judged by the Investigator;
  8. Abnormal pulse rate or blood pressure (BP) measurements at Screening, defined as: a. Pulse rate \<40 bpm or >100 bpm; b. Systolic BP \< 90 mmHg or >140 mmHg; or c. Diastolic BP \< 50 mmHg or > 90 mmHg.
  9. Clinically significant abnormalities at Screening or at Check-In (Day -1), defined as prolongation of the average QTcF interval > 450 ms for males and >470 ms for females, or other clinically significant ECG abnormalities per Investigator discretion;
  10. Positive for surface antigen, antibody, or virus antibody at Screening;
  11. Receipt of any product within 30 days prior to first study drug administration (90 days for investigational biologic agents) or 5 half-lives prior to first study drug administration, whichever is greater, or participation in >3 clinical studies within 12 months; 22. Known or suspected hypersensitivity to PATAS or any components of the formulation used (sodium hydroxide or mannitol);

Part 2: Multiple Ascending Dose Inclusion Criteria

  1. Male and female subjects, 18 to 65 years of age, inclusive, at the time of signing the ICF;
  2. Willing and able to give written for participation in the study prior to the initiation of any Screening or study-specific procedures;
  3. A diagnosis of T2D >6 months before Screening
  4. Subjects should be on a stable dose of

    1. an oral monotherapy (permitted monotherapies include metformin and dipeptidyl peptidase 4 inhibitors) for at least 90 days before Screening
    2. or a dual therapy (including metformin and dipeptidyl peptidase 4 inhibitors) for at least 6 months before Screening
    3. or managing the condition through diet and exercise for at least 90 days before Screening;
  5. 7 % and \<10.5% at Screening;
  6. within the range of 25.0 to 40.0 kg/m2, inclusive, at Screening;
  7. In generally good health, as judged by the Investigator, based upon medical/surgical history and the results of physical examination, vital signs, clinical laboratory assessments, and 12-lead ECG at Screening and at the pre-dose Check-In (Day -1);
  8. Female subjects must have a negative serum pregnancy test result at the Screening Visit and a negative urine pregnancy test at the pre-dose Check-In (Day -1) (priorto the first dose of study drug) and must not be pregnant, lactating, or planning a pregnancy from the Screening Visit to 90 days after the last dose of study drug;
  9. Female subjects of (i.e., ovulating, premenopausal, and not permanently surgically sterile) with male partners and all male subjects with female partners of childbearing potential will be included if they are either sexually inactive (complete abstinence from heterosexual activity if in line with the subject's preferred and usual lifestyle) and agree to continue complete abstinence for 90 days after the last administration of study drug, or, if sexually active, agree to use an effective regimen during their participation in the study and for 90 days after the last administration of study drug. Effective contraceptive methods are defined as those with 90% or greater efficacy and include the following:

    • For male subjects enrolled in the study: Condoms with spermicide; or Surgical sterilization (vasectomy) of the subject at least 6 months before Screening.
    • For female subjects enrolled in the study: Intrauterine device for at least 90 days before Screening; Hormonal contraception (combination oral contraceptives, progestin-only oral contraceptives that inhibit ovulation, hormonal implants, progestin only injections, rings, or patches) for at least 90 days before Screening; or Bilateral tubal ligation for at least 90 days before Screening.

    Note: Sexual abstinence is considered an effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. Abstinence is only acceptable if in line with the subject's preferred and usual lifestyle. Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea methods are not acceptable methods of contraception.

  10. Female subjects of nonchildbearing potential will be included if they meet the following definition of nonchildbearing potential: are either surgically sterile (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy at least 90 days before the Screening Visit) or , defined as spontaneous amenorrhea for at least 1 year, with FSH in the postmenopausal range at Screening, based on the central laboratory's ranges; and
  11. Willing to comply with all study procedures and requirements throughout the duration of the study.

Part 2 Multiple Ascending Dose Inclusion Criteria 1. Poorly controlled diabetes which will interfere with participation in the trial in the opinion of the Investigator, e.g., brittle diabetes, extreme fluctuation of glucoses; 2. History of diabetic ketoacidosis or hyperosmolar coma in the 6 months prior to Screening; 3. History of level 3 hypoglycemia in the 6 months prior to Screening or a history of hypoglycemia unawareness; 4. History or current evidence of type 1 diabetes or any other form of diabetes (e.g., latent diabetes in adults, maturity onset diabetes of the young, or secondary diabetes); 5. History of active or uncontrolled diabetic complications (i.e., neuropathy, retinopathy, nephropathy, gastroparesis); Note: Diabetic complications that are, in the opinion of the Investigator, stable in condition are permitted. 6. Clinically significant history of asthma, eczema, or any other allergic condition or previous severe hypersensitivity; Note: Non-active hay fever is not exclusionary. 7. Has an active or untreated or has been in remission from malignancy for 5 years except well-treated basal cell skin cancer or cervical cancer in situ; 8. Liver function tests (ALT, AST, ALP, total bilirubin) outside the following ULNs at Screening or at Check-In (Day -1):

  1. For ALT and AST, measurements 3× ULN;
  2. For ALP, measurements >2 × ULN; or
  3. For total bilirubin, measurements >1.5 × ULN. 9. TSH \<1 × LLN or TSH >1.5 × ULN at Screening; if a subject is on levothyroxine therapy, the subject should be on a stable dose for at least 6 weeks prior to Screening. 10. Estimated glomerular filtration rate 60 mL/min/1.73 m2 based on the CKD-EPI equation at Screening or at the pre-dose Check-In (Day -1); 11. History of unexplained syncope, cardiac arrest, unexplained cardiac arrythmias or torsades de pointes, or structural heart disease; 12. Personal or family history of long QT syndrome; 13. Clinically significant history of any disease or disorder (i.e., gastrointestinal, cardiovascular, respiratory, renal, hepatic, dermatological, or psychiatric) deemed to be exclusionary, as judged by the Investigator; 14. Recurrent or chronic pancreatitis 15. Abnormal pulse rate or BP measurements at Screening, defined as:

a. Pulse rate \<40 bpm or >100 bpm; b. Systolic BP \<90 mmHg or >160 mmHg; or c. Diastolic BP \<50 mmHg or >100 mmHg. 16. Clinically significant ECG abnormalities at Screening or at Check-In (Day -1), defined as prolongation of the average QTcF interval >450 ms for males and >470 ms for females, or other clinically significant ECG abnormalities per Investigator discretion; 17. Any other clinically significant laboratory abnormality deemed to be exclusionary, as judged by the Investigator; 18. Use of insulin, sulfonylureas, peroxisome proliferator activated receptor gamma agonists, pramlintide, sodium-glucose cotransporter 2 (SGLT2) inhibitors glucagon-like peptide-1 receptor agonists within 90 days prior to Screening; 19. Initiation of any newly prescribed or over-the-counter drugs (including vitamins, hormone replacement therapy, supplements, and natural and herbal remedies [e.g., St. John's wort]) within 90 days prior to Screening and throughout the duration of the study; Note: Paracetamol (up to 3 g per day) and contraceptives are permitted. Subjects taking prescription medications and over-the-counter medications for the treatment of concurrent medical conditions (i.e., antihypertensive agents, aspirin, lipid-lowering agents) are permitted if subjects have been on a stable dose for 30 days prior to Screening.

20. Use of systemic for 7 days or any in the 90 days prior to the pre-dose Check-In (Day -1); however, use of topical, ocular or inhaled steroids is permitted; 21. Positive urine drug screen (drugs of abuse) or urine cotinine test at Screening and/or the pre-dose Check-In (Day -1) or a history of drug/chemical abuse within 1 year prior to Screening; 22. Use of tobacco- or nicotine-containing products within 90 days prior to Screening or an unwillingness to abstain from the use of tobacco- or nicotine-containing products during the study; 23. Have typical weekly alcohol consumption of 14 alcoholic drinks. One drink is defined as 1 glass (approximately 10 to 12 oz) or 1 can (12 oz) of beer, 1 glass (approximately 4 to 5 oz) of wine, or 1 glass of distilled spirits (hard liquor) containing 1 oz of liquor; 24. Unwilling or unable to refrain from participating in contact sports or unaccustomed strenuous exercise for at least 72 hours prior to Screening, 72 hours prior to the first admission to the clinical site (e.g., the pre-dose Check-In [Day - 1]), and 72 hours prior to the visits to the clinical site on Day 8, Day 15, and Day 22 and the Follow-Up Visits on Day 28 and Day 35; 25. Unwilling to refrain from consuming liquids or foods containing caffeine or other xanthines from 48 hours prior to each admission to the clinical site (e.g., the predose Check-In [Day -1], Day 8, Day 15, and Day 22). Subjects should also refrain from consuming liquids or foods containing caffeine or other xanthines for 48 hours prior to the Follow-Up Visits on Day 28 and Day 35; 26. Subjects with extensive abdominal scarring, lipodystrophy, abdominal tattoos, or other such issues with the abdomen that would restrict the ability to perform multiple injections to the abdomen, per Investigator discretion; Note: Subjects are discouraged from getting abdominal tattoos during the study. 27. Lost or donated 450 mL of blood or blood products within 90 days prior to Screening, received a transfusion within 90 days prior to Screening, or plan to donate during the course of the study; 28. Positive for hepatitis B surface antigen, HIV antibody, or hepatitis C virus antibody at Screening; 29. Receipt of any investigational product within 30 days prior to first study drug administration (90 days for investigational biologic agents) or 5 half-lives, whichever is greater, or participation in >3 clinical studies within 12 months; 30. Known or suspected hypersensitivity to PATAS or any components of the formulation used (sodium hydroxide or mannitol); or 31. Employee of the Sponsor, the CRO, or the clinical site (e.g., permanent employee, temporary contract worker, or designee responsible for the conduct of the study) or family members (e.g., spouse, parent, sibling, or child) of the Sponsor, CRO, or other clinical site employee

Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
56 participants (estimated)

Study arms

  • Placebo comparator
    Diabetic subjects, Placebo

    Drug: Placebo

  • Experimental
    Diabetic Subjects, Active

    Drug: PATAS Trifluoroacetate

Interventions

  • DrugPATAS Trifluoroacetate

    A drug targeting the interaction between the ALMS1 protein and alpha-PKC

  • DrugPlacebo

    Excipient only formulation, without active compound

06

What researchers measure

Primary outcomes

  1. Phase 1B: Safety

    Incidence and severity (using CTCAE version 5.0.) of treatment-emergent AEs and SAEs

    Time frame: 29 days

  2. OGTT

    Oral glucose tolerance test

    Time frame: Baseline, Day 28

  3. Cmax

    Maximum observed plasma concentration

    Time frame: Pre-dose, Day 1, Day 2, Day 8, Day 15, Day 22, Day 23

  4. Tmax

    Time to Cmax

    Time frame: Pre-dose, Day 1, Day 2, Day 8, Day 15, Day 22, Day 23

  5. AUClast

    Area under the concentration-time curve (AUC) from time 0 to the last measurable plasma concentration

    Time frame: Pre-dose, Day 1, Day 2, Day 8, Day 15, Day 22, Day 23

  6. AUCinf

    AUC extrapolated to infinity (AUCinf);

    Time frame: Pre-dose, Day 1, Day 2, Day 8, Day 15, Day 22, Day 23

  7. T1/2

    Apparent plasma terminal elimination half-life

    Time frame: Pre-dose, Day 1, Day 2, Day 8, Day 15, Day 22, Day 23

  8. CL/F

    Apparent total plasma clearance after SC injection

    Time frame: Pre-dose, Day 1, Day 2, Day 8, Day 15, Day 22, Day 23

  9. HOMA-IR

    Homeostatic Model Assessment of Insulin Resistance

    Time frame: Baseline, Day 28

  10. TyG

    Changes in triglyceride-glucose index

    Time frame: Baseline, Day 28

  11. Adipo-IR

    Changes in Adipose Tissue Insulin Resistance Index

    Time frame: Baseline, Day 28

  12. Changes in glucose and insulin levels

    Changes in glucose and insulin levels

    Time frame: Baseline, Day 28

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — This data is confidential.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for May 2027, 16 months after the start.

Of 454 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's planned 16 months is above that.

Counting every sponsor, half of 517 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Jul 2026 → May 2027 and completion Sep 2026 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2025
First posted
Oct 31, 2025
StartActual
Jan 27, 2026
Primary completionEst.
May 30, 2027was Jul 2026
CompletionEst.
May 30, 2027was Sep 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Sep 29, 2026
Sites
3 sites added, 2 sites removed. 3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • Arizona Clinical Trials · Chandler, United Statesno status→Recruiting
  • Clinical Pharmacology of Miami · Miami, United Statesno status→Recruiting
  • Progressive Medical Research · Port Orange, United Statesno status→Recruiting
Show 3 added (3 United States)
  • Arizona Clinical Trials · Chandler, United States
  • Clinical Pharmacology of Miami · Miami, United States
  • Progressive Medical Research · Port Orange, United States
Show 2 removed
  • Medpace Clinical Pharmacology Unit · Cincinnati, United States
  • Medpace Clinical Pharmaology Unit · Cincinnati, United States
across 2 updates, Sep 25, 2026 – Sep 29, 2026
Primary completion
Jul 30, 2026→May 30, 2027
Sep 25, 2026
Study completion
Sep 30, 2026→May 30, 2027
Sep 25, 2026
Eligibility
Maximum age 55 Years→65 Years; 25 exclusion criteria added
What changed in the criteria
Exclusion criteria
  • Added<!-- -->
  • AddedPart 2: Multiple Ascending Dose Inclusion Criteria
  • AddedMale and female subjects, 18 to 65 years of age, inclusive, at the time of signing the ICF;
  • AddedWilling and able to give written informed consent for participation in the study prior to the initiation of any Screening or study-specific procedures;
  • AddedA diagnosis of T2D >6 months before Screening
  • AddedSubjects should be on a stable dose of
  • Addedan oral monotherapy (permitted monotherapies include metformin and dipeptidyl peptidase 4 inhibitors) for at least 90 days before Screening
  • Addedor a dual therapy (including metformin and dipeptidyl peptidase 4 inhibitors) for at least 6 months before Screening
  • Addedor managing the condition through diet and exercise for at least 90 days before Screening;
  • AddedGlycated hemoglobin 7 % and <10.5% at Screening;
  • AddedBMI within the range of 25.0 to 40.0 kg/m2, inclusive, at Screening;
  • AddedIn generally good health, as judged by the Investigator, based upon medical/surgical history and the results of physical examination, vital signs, clinical laboratory assessments, and 12-lead ECG at Screening and at the pre-dose Check-In (Day -1);
  • AddedFemale subjects must have a negative serum pregnancy test result at the Screening Visit and a negative urine pregnancy test at the pre-dose Check-In (Day -1) (priorto the first dose of study drug) and must not be pregnant, lactating, or planning a pregnancy from the Screening Visit to 90 days after the last dose of study drug;
  • AddedFemale subjects of childbearing potential (i.e., ovulating, premenopausal, and not permanently surgically sterile) with male partners and all male subjects with female partners of childbearing potential will be included if they are either sexually inactive (complete abstinence from heterosexual activity if in line with the subject's preferred and usual lifestyle) and agree to continue complete abstinence for 90 days after the last administration of study drug, or, if sexually active, agree to use an effective contraceptive regimen during their participation in the study and for 90 days after the last administration of study drug. Effective contraceptive methods are defined as those with 90% or greater efficacy and include the following:
  • AddedFor male subjects enrolled in the study: Condoms with spermicide; or Surgical sterilization (vasectomy) of the subject at least 6 months before Screening.
  • AddedFor female subjects enrolled in the study: Intrauterine device for at least 90 days before Screening; Hormonal contraception (combination oral contraceptives, progestin-only oral contraceptives that inhibit ovulation, hormonal implants, progestin only injections, rings, or patches) for at least 90 days before Screening; or Bilateral tubal ligation for at least 90 days before Screening.
  • AddedNote: Sexual abstinence is considered an effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. Abstinence is only acceptable if in line with the subject's preferred and usual lifestyle. Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea methods are not acceptable methods of contraception.
  • AddedFemale subjects of nonchildbearing potential will be included if they meet the following definition of nonchildbearing potential: are either surgically sterile (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy at least 90 days before the Screening Visit) or postmenopausal, defined as spontaneous amenorrhea for at least 1 year, with FSH in the postmenopausal range at Screening, based on the central laboratory's ranges; and
  • AddedWilling to comply with all study procedures and requirements throughout the duration of the study.
  • AddedPart 2 Multiple Ascending Dose Inclusion Criteria 1. Poorly controlled diabetes which will interfere with participation in the trial in the opinion of the Investigator, e.g., brittle diabetes, extreme fluctuation of glucoses; 2. History of diabetic ketoacidosis or hyperosmolar coma in the 6 months prior to Screening; 3. History of level 3 hypoglycemia in the 6 months prior to Screening or a history of hypoglycemia unawareness; 4. History or current evidence of type 1 diabetes or any other form of diabetes (e.g., latent autoimmune diabetes in adults, maturity onset diabetes of the young, or secondary diabetes); 5. History of active or uncontrolled diabetic complications (i.e., neuropathy, retinopathy, nephropathy, gastroparesis); Note: Diabetic complications that are, in the opinion of the Investigator, stable in condition are permitted. 6. Clinically significant history of asthma, eczema, or any other allergic condition or previous severe hypersensitivity; Note: Non-active hay fever is not exclusionary. 7. Has an active or untreated malignancy or has been in remission from malignancy for 5 years except well-treated basal cell skin cancer or cervical cancer in situ; 8. Liver function tests (ALT, AST, ALP, total bilirubin) outside the following ULNs at Screening or at Check-In (Day -1):
  • AddedFor ALT and AST, measurements 3× ULN;
  • AddedFor ALP, measurements >2 × ULN; or
  • AddedFor total bilirubin, measurements >1.5 × ULN. 9. TSH <1 × LLN or TSH >1.5 × ULN at Screening; if a subject is on levothyroxine therapy, the subject should be on a stable dose for at least 6 weeks prior to Screening. 10. Estimated glomerular filtration rate 60 mL/min/1.73 m2 based on the CKD-EPI equation at Screening or at the pre-dose Check-In (Day -1); 11. History of unexplained syncope, cardiac arrest, unexplained cardiac arrythmias or torsades de pointes, or structural heart disease; 12. Personal or family history of long QT syndrome; 13. Clinically significant history of any disease or disorder (i.e., gastrointestinal, cardiovascular, respiratory, renal, hepatic, dermatological, or psychiatric) deemed to be exclusionary, as judged by the Investigator; 14. Recurrent or chronic pancreatitis 15. Abnormal pulse rate or BP measurements at Screening, defined as:
  • AddedPulse rate <40 bpm or >100 bpm; b. Systolic BP <90 mmHg or >160 mmHg; or c. Diastolic BP <50 mmHg or >100 mmHg. 16. Clinically significant ECG abnormalities at Screening or at Check-In (Day -1), defined as prolongation of the average QTcF interval >450 ms for males and >470 ms for females, or other clinically significant ECG abnormalities per Investigator discretion; 17. Any other clinically significant laboratory abnormality deemed to be exclusionary, as judged by the Investigator; 18. Use of insulin, sulfonylureas, peroxisome proliferator activated receptor gamma agonists, pramlintide, sodium-glucose cotransporter 2 (SGLT2) inhibitors glucagon-like peptide-1 receptor agonists within 90 days prior to Screening; 19. Initiation of any newly prescribed or over-the-counter drugs (including vitamins, hormone replacement therapy, supplements, and natural and herbal remedies [e.g., St. John's wort]) within 90 days prior to Screening and throughout the duration of the study; Note: Paracetamol (up to 3 g per day) and contraceptives are permitted. Subjects taking prescription medications and over-the-counter medications for the treatment of concurrent medical conditions (i.e., antihypertensive agents, aspirin, lipid-lowering agents) are permitted if subjects have been on a stable dose for 30 days prior to Screening.
  • Added20. Use of systemic steroids for 7 days or any immunosuppressants in the 90 days prior to the pre-dose Check-In (Day -1); however, use of topical, ocular or inhaled steroids is permitted; 21. Positive urine drug screen (drugs of abuse) or urine cotinine test at Screening and/or the pre-dose Check-In (Day -1) or a history of drug/chemical abuse within 1 year prior to Screening; 22. Use of tobacco- or nicotine-containing products within 90 days prior to Screening or an unwillingness to abstain from the use of tobacco- or nicotine-containing products during the study; 23. Have typical weekly alcohol consumption of 14 alcoholic drinks. One drink is defined as 1 glass (approximately 10 to 12 oz) or 1 can (12 oz) of beer, 1 glass (approximately 4 to 5 oz) of wine, or 1 glass of distilled spirits (hard liquor) containing 1 oz of liquor; 24. Unwilling or unable to refrain from participating in contact sports or unaccustomed strenuous exercise for at least 72 hours prior to Screening, 72 hours prior to the first admission to the clinical site (e.g., the pre-dose Check-In [Day - 1]), and 72 hours prior to the visits to the clinical site on Day 8, Day 15, and Day 22 and the Follow-Up Visits on Day 28 and Day 35; 25. Unwilling to refrain from consuming liquids or foods containing caffeine or other xanthines from 48 hours prior to each admission to the clinical site (e.g., the predose Check-In [Day -1], Day 8, Day 15, and Day 22). Subjects should also refrain from consuming liquids or foo…
Sep 25, 2026
Interventions
Arm changed Healthy subjects, Placebo→Diabetic subjects, Placebo; Healthy Subjects, Active→Diabetic Subjects, Active
Sep 25, 2026
Primary outcomes
12 added, 1 removed
What changed in the outcomes
  • AddedPhase 1B: SafetyTime frame: 29 days
  • AddedOGTTTime frame: Baseline, Day 28
  • AddedCmaxTime frame: Pre-dose, Day 1, Day 2, Day 8, Day 15, Day 22, Day 23
  • AddedTmaxTime frame: Pre-dose, Day 1, Day 2, Day 8, Day 15, Day 22, Day 23
  • AddedAUClastTime frame: Pre-dose, Day 1, Day 2, Day 8, Day 15, Day 22, Day 23
  • AddedAUCinfTime frame: Pre-dose, Day 1, Day 2, Day 8, Day 15, Day 22, Day 23
  • AddedT1/2Time frame: Pre-dose, Day 1, Day 2, Day 8, Day 15, Day 22, Day 23
  • AddedCL/FTime frame: Pre-dose, Day 1, Day 2, Day 8, Day 15, Day 22, Day 23
  • AddedHOMA-IRTime frame: Baseline, Day 28
  • AddedTyGTime frame: Baseline, Day 28
  • AddedAdipo-IRTime frame: Baseline, Day 28
  • AddedChanges in glucose and insulin levelsTime frame: Baseline, Day 28
  • RemovedSafety -- 1ATime frame: 29 days
Sep 25, 2026
Contact
Study contact now listed: added t•••@adipopharma.us · •••7158; added m•••@adipopharma.us · •••4351. See the current contact
Sep 29, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Arizona Clinical Trials · Chandler, United StatesContact added s•••@azclinicaltrials.com · •••4000Contact added (no phone or email listed)
  • Clinical Pharmacology of Miami · Miami, United StatesContact added D•••@ergclinical.comContact added (no phone or email listed)
  • Progressive Medical Research · Port Orange, United StatesContact added J•••@progressivemedicalresearch.com · •••7070Contact added (no phone or email listed)
Sep 29, 2026
Title
A Study of PATAS Trifluoroacetate Using Single Ascending Doses in Healthy Volunteers and Multiple Ascending Doses in Diabetic Subjects
Sep 25, 2026
Show all 2 updates
  1. Sep 29, 2026
    Active, not recruiting→Recruiting
    3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • Arizona Clinical Trials · Chandler, United Statesno status→Recruiting
    • Clinical Pharmacology of Miami · Miami, United Statesno status→Recruiting
    • Progressive Medical Research · Port Orange, United Statesno status→Recruiting
    Contact Study contact now listed: added t•••@adipopharma.us · •••7158; added m•••@adipopharma.us · •••4351. See the current contact
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Arizona Clinical Trials · Chandler, United StatesContact added s•••@azclinicaltrials.com · •••4000Contact added (no phone or email listed)
    • Clinical Pharmacology of Miami · Miami, United StatesContact added D•••@ergclinical.comContact added (no phone or email listed)
    • Progressive Medical Research · Port Orange, United StatesContact added J•••@progressivemedicalresearch.com · •••7070Contact added (no phone or email listed)
  2. Sep 25, 2026
    3 sites added, 2 sites removed
    Show 3 added (3 United States)
    • Arizona Clinical Trials · Chandler, United States
    • Clinical Pharmacology of Miami · Miami, United States
    • Progressive Medical Research · Port Orange, United States
    Show 2 removed
    • Medpace Clinical Pharmacology Unit · Cincinnati, United States
    • Medpace Clinical Pharmaology Unit · Cincinnati, United States
    Primary completion Jul 30, 2026→May 30, 2027
    Study completion Sep 30, 2026→May 30, 2027
    Eligibility Maximum age 55 Years→65 Years; 25 exclusion criteria added
    What changed in the criteria
    Exclusion criteria
    • Added<!-- -->
    • AddedPart 2: Multiple Ascending Dose Inclusion Criteria
    • AddedMale and female subjects, 18 to 65 years of age, inclusive, at the time of signing the ICF;
    • AddedWilling and able to give written informed consent for participation in the study prior to the initiation of any Screening or study-specific procedures;
    • AddedA diagnosis of T2D >6 months before Screening
    • AddedSubjects should be on a stable dose of
    • Addedan oral monotherapy (permitted monotherapies include metformin and dipeptidyl peptidase 4 inhibitors) for at least 90 days before Screening
    • Addedor a dual therapy (including metformin and dipeptidyl peptidase 4 inhibitors) for at least 6 months before Screening
    • Addedor managing the condition through diet and exercise for at least 90 days before Screening;
    • AddedGlycated hemoglobin 7 % and <10.5% at Screening;
    • AddedBMI within the range of 25.0 to 40.0 kg/m2, inclusive, at Screening;
    • AddedIn generally good health, as judged by the Investigator, based upon medical/surgical history and the results of physical examination, vital signs, clinical laboratory assessments, and 12-lead ECG at Screening and at the pre-dose Check-In (Day -1);
    • AddedFemale subjects must have a negative serum pregnancy test result at the Screening Visit and a negative urine pregnancy test at the pre-dose Check-In (Day -1) (priorto the first dose of study drug) and must not be pregnant, lactating, or planning a pregnancy from the Screening Visit to 90 days after the last dose of study drug;
    • AddedFemale subjects of childbearing potential (i.e., ovulating, premenopausal, and not permanently surgically sterile) with male partners and all male subjects with female partners of childbearing potential will be included if they are either sexually inactive (complete abstinence from heterosexual activity if in line with the subject's preferred and usual lifestyle) and agree to continue complete abstinence for 90 days after the last administration of study drug, or, if sexually active, agree to use an effective contraceptive regimen during their participation in the study and for 90 days after the last administration of study drug. Effective contraceptive methods are defined as those with 90% or greater efficacy and include the following:
    • AddedFor male subjects enrolled in the study: Condoms with spermicide; or Surgical sterilization (vasectomy) of the subject at least 6 months before Screening.
    • AddedFor female subjects enrolled in the study: Intrauterine device for at least 90 days before Screening; Hormonal contraception (combination oral contraceptives, progestin-only oral contraceptives that inhibit ovulation, hormonal implants, progestin only injections, rings, or patches) for at least 90 days before Screening; or Bilateral tubal ligation for at least 90 days before Screening.
    • AddedNote: Sexual abstinence is considered an effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. Abstinence is only acceptable if in line with the subject's preferred and usual lifestyle. Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea methods are not acceptable methods of contraception.
    • AddedFemale subjects of nonchildbearing potential will be included if they meet the following definition of nonchildbearing potential: are either surgically sterile (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy at least 90 days before the Screening Visit) or postmenopausal, defined as spontaneous amenorrhea for at least 1 year, with FSH in the postmenopausal range at Screening, based on the central laboratory's ranges; and
    • AddedWilling to comply with all study procedures and requirements throughout the duration of the study.
    • AddedPart 2 Multiple Ascending Dose Inclusion Criteria 1. Poorly controlled diabetes which will interfere with participation in the trial in the opinion of the Investigator, e.g., brittle diabetes, extreme fluctuation of glucoses; 2. History of diabetic ketoacidosis or hyperosmolar coma in the 6 months prior to Screening; 3. History of level 3 hypoglycemia in the 6 months prior to Screening or a history of hypoglycemia unawareness; 4. History or current evidence of type 1 diabetes or any other form of diabetes (e.g., latent autoimmune diabetes in adults, maturity onset diabetes of the young, or secondary diabetes); 5. History of active or uncontrolled diabetic complications (i.e., neuropathy, retinopathy, nephropathy, gastroparesis); Note: Diabetic complications that are, in the opinion of the Investigator, stable in condition are permitted. 6. Clinically significant history of asthma, eczema, or any other allergic condition or previous severe hypersensitivity; Note: Non-active hay fever is not exclusionary. 7. Has an active or untreated malignancy or has been in remission from malignancy for 5 years except well-treated basal cell skin cancer or cervical cancer in situ; 8. Liver function tests (ALT, AST, ALP, total bilirubin) outside the following ULNs at Screening or at Check-In (Day -1):
    • AddedFor ALT and AST, measurements 3× ULN;
    • AddedFor ALP, measurements >2 × ULN; or
    • AddedFor total bilirubin, measurements >1.5 × ULN. 9. TSH <1 × LLN or TSH >1.5 × ULN at Screening; if a subject is on levothyroxine therapy, the subject should be on a stable dose for at least 6 weeks prior to Screening. 10. Estimated glomerular filtration rate 60 mL/min/1.73 m2 based on the CKD-EPI equation at Screening or at the pre-dose Check-In (Day -1); 11. History of unexplained syncope, cardiac arrest, unexplained cardiac arrythmias or torsades de pointes, or structural heart disease; 12. Personal or family history of long QT syndrome; 13. Clinically significant history of any disease or disorder (i.e., gastrointestinal, cardiovascular, respiratory, renal, hepatic, dermatological, or psychiatric) deemed to be exclusionary, as judged by the Investigator; 14. Recurrent or chronic pancreatitis 15. Abnormal pulse rate or BP measurements at Screening, defined as:
    • AddedPulse rate <40 bpm or >100 bpm; b. Systolic BP <90 mmHg or >160 mmHg; or c. Diastolic BP <50 mmHg or >100 mmHg. 16. Clinically significant ECG abnormalities at Screening or at Check-In (Day -1), defined as prolongation of the average QTcF interval >450 ms for males and >470 ms for females, or other clinically significant ECG abnormalities per Investigator discretion; 17. Any other clinically significant laboratory abnormality deemed to be exclusionary, as judged by the Investigator; 18. Use of insulin, sulfonylureas, peroxisome proliferator activated receptor gamma agonists, pramlintide, sodium-glucose cotransporter 2 (SGLT2) inhibitors glucagon-like peptide-1 receptor agonists within 90 days prior to Screening; 19. Initiation of any newly prescribed or over-the-counter drugs (including vitamins, hormone replacement therapy, supplements, and natural and herbal remedies [e.g., St. John's wort]) within 90 days prior to Screening and throughout the duration of the study; Note: Paracetamol (up to 3 g per day) and contraceptives are permitted. Subjects taking prescription medications and over-the-counter medications for the treatment of concurrent medical conditions (i.e., antihypertensive agents, aspirin, lipid-lowering agents) are permitted if subjects have been on a stable dose for 30 days prior to Screening.
    • Added20. Use of systemic steroids for 7 days or any immunosuppressants in the 90 days prior to the pre-dose Check-In (Day -1); however, use of topical, ocular or inhaled steroids is permitted; 21. Positive urine drug screen (drugs of abuse) or urine cotinine test at Screening and/or the pre-dose Check-In (Day -1) or a history of drug/chemical abuse within 1 year prior to Screening; 22. Use of tobacco- or nicotine-containing products within 90 days prior to Screening or an unwillingness to abstain from the use of tobacco- or nicotine-containing products during the study; 23. Have typical weekly alcohol consumption of 14 alcoholic drinks. One drink is defined as 1 glass (approximately 10 to 12 oz) or 1 can (12 oz) of beer, 1 glass (approximately 4 to 5 oz) of wine, or 1 glass of distilled spirits (hard liquor) containing 1 oz of liquor; 24. Unwilling or unable to refrain from participating in contact sports or unaccustomed strenuous exercise for at least 72 hours prior to Screening, 72 hours prior to the first admission to the clinical site (e.g., the pre-dose Check-In [Day - 1]), and 72 hours prior to the visits to the clinical site on Day 8, Day 15, and Day 22 and the Follow-Up Visits on Day 28 and Day 35; 25. Unwilling to refrain from consuming liquids or foods containing caffeine or other xanthines from 48 hours prior to each admission to the clinical site (e.g., the predose Check-In [Day -1], Day 8, Day 15, and Day 22). Subjects should also refrain from consuming liquids or foo…
    Primary outcomes 12 added, 1 removed
    What changed in the outcomes
    • AddedPhase 1B: SafetyTime frame: 29 days
    • AddedOGTTTime frame: Baseline, Day 28
    • AddedCmaxTime frame: Pre-dose, Day 1, Day 2, Day 8, Day 15, Day 22, Day 23
    • AddedTmaxTime frame: Pre-dose, Day 1, Day 2, Day 8, Day 15, Day 22, Day 23
    • AddedAUClastTime frame: Pre-dose, Day 1, Day 2, Day 8, Day 15, Day 22, Day 23
    • AddedAUCinfTime frame: Pre-dose, Day 1, Day 2, Day 8, Day 15, Day 22, Day 23
    • AddedT1/2Time frame: Pre-dose, Day 1, Day 2, Day 8, Day 15, Day 22, Day 23
    • AddedCL/FTime frame: Pre-dose, Day 1, Day 2, Day 8, Day 15, Day 22, Day 23
    • AddedHOMA-IRTime frame: Baseline, Day 28
    • AddedTyGTime frame: Baseline, Day 28
    • AddedAdipo-IRTime frame: Baseline, Day 28
    • AddedChanges in glucose and insulin levelsTime frame: Baseline, Day 28
    • RemovedSafety -- 1ATime frame: 29 days
    Interventions Arm changed Healthy subjects, Placebo→Diabetic subjects, Placebo; Healthy Subjects, Active→Diabetic Subjects, Active
    Title A Study of PATAS Trifluoroacetate Using Single Ascending Doses in Healthy Volunteers and Multiple Ascending Doses in Diabetic Subjects
    + 3 other changes: verification date, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07223333
Lead sponsor
AdipoPharma LLC
Responsible party
Sponsor
First posted
Oct 31, 2025
Start date
Jan 27, 2026
Primary completion
May 30, 2027 (estimated)
Completion
May 30, 2027 (estimated)
Last update
Sep 29, 2026

Study contacts

Tarek Hiwot, M.D.
Contact
tarek.hiwot@adipopharma.us
44 7391 537 158
Michael J Fare
Contact
michael.fare@adipopharma.us
203-671-4351
Vincent Marion, Ph.D.
study chair · AdipoPharma LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion